RxDoctor Payments Data

Heather Fritts

Family · Florence, ALNPI 1225578123

Payments from drug & device makers

$8,873in general payments, 2019–2025

Across 542 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$775
  • AstraZeneca$759
  • Novartis$693
  • Lilly USA, LLC$546
  • Johnson & Johnson$489
  • Merck$483
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$8,79099%
  • Education$831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk65$775
AstraZeneca(2 entities)35$759
Novartis43$693
Lilly USA, LLC44$546
Johnson & Johnson(2 entities)24$489
Merck24$483
AbbVie47$448
Takeda Pharmaceuticals U.S.A., Inc.24$419
Pfizer21$346
Bayer16$278
GSK18$251
Seagen Inc.11$246
Astellas Pharma US Inc11$225
Incyte Corporation9$182
Beone Medicines USA, Inc.9$169
Genentech USA, Inc.9$166
Boehringer Ingelheim9$164
Amarin Pharma, Inc.10$161
Amgen(2 entities)11$152
E.r. Squibb & Sons, L.L.C.8$139
Sanofi6$115
Daiichi Sankyo Inc.5$101
Tersera Therapeutics LLC4$94
Blueprint Medicines Corporation3$75
Stemline Therapeutics Inc.3$68
Bristol Myers Squibb3$60
Eisai Inc.3$56
Recordati_rare_diseases_inc.3$55
Exelixis Inc.2$54
Pharmacyclics LLC, An Abbvie Company3$53
Pharmaessentia USA Corporation3$53
AVEO Pharmaceuticals, Inc.3$50
Ironwood Pharmaceuticals, Inc3$47
Iovance Biotherapeutics, Inc.3$46
Biohaven Pharmaceuticals, Inc.3$44
Coherus Oncology, Inc.2$43
Sumitomo Pharma America, Inc.2$43
Mirati Therapeutics, Inc.2$42
Beigene USA, Inc.2$42
Geron Corporation2$41
Sanofi-aventis U.S. LLC2$38
Jazz Pharmaceuticals Inc.2$37
Adaptive Biotechnologies Corporation2$36
Array Biopharma Inc2$35
Acrotech Biopharma Inc.2$34
Biohaven Pharmaceutical Holding Company Ltd.2$32
Dendreon Pharmaceuticals LLC1$32
Dexcom, Inc.2$30
Regeneron Healthcare Solutions, Inc.2$29
Sun Pharmaceutical Industries Inc.1$29
Deciphera Pharmaceuticals Inc.1$26
Kyowa Kirin, Inc.1$21
Sobi, Inc1$21
Tolmar, Inc.1$20
Apellis Pharmaceuticals, Inc.1$19
Servier Pharmaceuticals LLC1$18
EMD Serono, Inc.1$18
Puma Biotechnology, Inc.1$17
Abbott1$17
Agios Pharmaceuticals, Inc.1$16

How this compares

$8,873 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$32,338
Medicare patients
190
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib12$155,318
Exemestane17$2,220
Letrozole28$1,916
Acyclovir14$695
Potassium Chloride47$661
Anastrozole37$537
Dexamethasone24$455
Ondansetron OdtOndansetron22$363
Pantoprazole Sodium22$203
Albuterol Sulfate HfaAlbuterol Sulfate16$197
Prednisone41$176
Cefdinir11$148
Ondansetron Hcl16$131
Triamcinolone Acetonide16$70
Warfarin Sodium17$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$42$155,31812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Florence

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →